Table. Characteristics of Trials Included in the Meta-Analysis.
| Source | Phase | Randomized | Open label | Rating | Disease | Total No. of patients (I/C)a | Interventionb | Control | Median age, y | |
|---|---|---|---|---|---|---|---|---|---|---|
| I | C | |||||||||
| Gettinger et al,4 2021 | 3 | Yes | Yes | 1 | Metastatic squamous cell lung cancer | 252 (125/127) | Nivolumab, 3 mg/kg every 2 wk, plus ipilimumab, 1 mg/kg every 6 wk until progression | Nivolumab, 3 mg/kg every 2 wk | 67.5 | 68.1 |
| Hellmann et al,5 2019 | 3 | Yes | Yes | 1 | Metastatic or recurrent NSCLC with PD-L1 ≥ 1% | 792 (396/ 396) | Nivolumab, 3 mg/kg every 2 wk, plus ipilimumab, 1 mg/kg every 6 wk until progression | Nivolumab, 240 mg every 2 wk | 64 | 64 |
| Scherpereel et al,7 2019 | 2 | Yes | Yes | 2 | Relapsed pleural mesothelioma | 125 (62/63) | Nivolumab, 3 mg/kg every 2 wk, plus ipilimumab, 1 mg/kg every 6 wk until progression | Nivolumab, 3 mg/kg every 2 wk | 71.2 | 72.3 |
| Sharma et al,8 2019 | 1/2 | No | Yes | 2 | Metastatic urothelial carcinoma | 182 (104/78) | Nivolumab, 3 mg/kg every 3 wk, plus ipilimumab, 1 mg/kg every 3 wk, for 4 doses followed by nivolumab, 3 mg/kg for every 2-week maintenance | Nivolumab, 3 mg/kg every 2 wk | 63 | 65.5 |
| Janjigian et al,9 2018 | 1/2 | No | Yes | 2 | Metastatic esophagogastric carcinoma | 111 (52/59) | Nivolumab, 3 mg/kg every 3 wk, plus ipilimumab, 1 mg/kg every 3 wk, for 4 doses followed by nivolumab, 3 mg/kg for every 2-week maintenance | Nivolumab, 3 mg/kg every 2 wk | 58 | 60 |
| D’Angelo et al,10 2018 | 2 | Yes | Yes | 2 | Advanced sarcoma | 83 (41/42) | Nivolumab, 3 mg/kg every 3 wk, plus ipilimumab, 1 mg/kg every 3 wk, for 4 doses followed by nivolumab, 3 mg/kg for every 2-week maintenance | Nivolumab, 3 mg/kg every 2 wk | 57 | 56 |
| Omuro, et al,11 2018 | 1 | No | Yes | 2 | Glioblastoma multiforme | 30 (20/10) | Nivolumab, 3 mg/kg every 3 wk, plus ipilimumab, 1 mg/kg every 3 wk, for 4 doses followed by nivolumab, 3 mg/kg for every 2-week maintenance | Nivolumab, 3 mg/kg every 2 wk | 60 | 58.5 |
| Antonia, et al,6 2016 | 1/2 | No | Yes | 2 | Recurrent small cell lung cancer | 152 (54/98) | Nivolumab, 3 mg/kg every 2 wk, plus ipilimumab, 1 mg/kg for every 3 wk, for 4 doses followed by nivolumab, 3 mg/kg for every 2-week maintenance | Nivolumab, 3 mg/kg every 2 wk | 61 | 63 |
Abbreviations: I, intervention; C, control; NSCLC, non–small cell lung cancer; PD-L1 programmed death ligand 1.
a
Total patients includes patients in the ipilimumab and standard-dose nivolumab and standard-dose nivolumab arms and excludes other patients and arms.
b
Trials may have included other dosing arms but were excluded from this meta-analysis.